

Gold Coast Hospital and Health Service to trial the use of the HeraCARE Platform for high-risk pregnancies for their Women Newborn and Children Services (WNCS)

- The Gold Coast Hospital and Health Service (GCHHS) is currently undertaking an ambitious digital transformation program for the health service under their Digital 2024 (D24) strategic plan;
- GCHHS recently signed a Memorandum of Understanding (MoU) to trial the use of the HeraCARE platform as its new standard of care for their Women Newborn and Children Services (WNCS);
- A controlled trial of HeraCARE platform will begin for up to 90 pregnancies for a period of six to nine months with an objective to evaluate clinical usability, patient satisfaction, value for money and economic analysis;
- Upon successful completion of the trial, subject to a proper market scan, value for money assessment and results of clinical outcomes, GCHHS intends to order additional licenses; and
- GCHHS currently manages more than 5000 pregnancies each year and upon the success of the pilot program, 'Connected Maternity Care' using HeraCARE platform may become a standard maternity care model.

HeraMED Limited (ASX:HMD) ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce that it has signed an MOU with the Gold Coast Hospital to trial the HeraCARE platform as its new standard of care for their Women Newborn and Children Services (WNCS).

Initially, a controlled trial of the HeraCARE platform will be undertaken for up to 90 pregnancies for a period of six to nine months with an objective to evaluate clinical usability, patient satisfaction, value for money and economic analysis.

Concurrently, HeraMED will work with Gold Coast Health to undertake a Clinical implementation study to assess several use cases including acceptance, cost effective analysis and clinical outcomes.

On successful completion of the trial, subject to a proper market scan, value for money assessment and results of clinical outcomes, GCHHS intends to order additional licences.

HeraMED CEO and Cofounder, Mr David Groberman said: "This MOU represents a significant milestone for HeraMED and an important validation of our technology and business model and is our first major win with a government establishment on the Australian East Coast.

"I would like to take this opportunity to congratulate the entire team and in particular Anoushka Gungadin and Ady Jakubovitz, who have successfully navigated the rigorous evaluation and testing processes that exist across healthcare, to finalise this MOU.

“The Gold Coast Hospital is leading the way in digitisation of healthcare, and we are delighted that they are planning to adopt our technology as their standard of care for remote pregnancy monitoring,” he said.

HeraMED Director of Strategic Partnerships, Australia and New Zealand (ANZ), Anoushka Gungadin said: “Gold Coast Health is one of the most credible Australian organisations, innovative, future-focused and a leader in digital transformation of healthcare and I’m delighted to have reached this collaborative partnership with them.”

Gold Coast Health Executive Director Strategy, Transformation and Major Capital, Sandip Kumar said: “Having successfully completed the first stage of our transformation agenda which was to digitally enable our health service, the focus now is to leverage new technologies to improve the quality and experience of patient care and we expect the HeraCARE platform will deliver on these goals as our new standard of care.

About Gold Coast Health

Gold Coast Health is an internationally recognised health institution that has embraced digital transformation and innovation to improve patient care and patient experience.

GCHHS services a population of more than 600,000, with a patient catchment between the northern Gold Coast and the New South Wales border and a high annual number of visitors and tourists. GCHHS also provides services to patients in northern NSW, where those services are not provided within the area. Gold Coast Health manages more than 20 physical facilities including three hospitals and two health precincts.

Investor Webinar

HeraMED CEO and Cofounder, Mr David Groberman and HeraMED Director of Strategic Partnerships (ANZ) Anoushka Gungadin will host an investor webinar at 10.30am AEDT on 22 March 2023, to provide investors with an opportunity to hear more about this partnership.

To attend the webinar, please register using the following link:

https://us02web.zoom.us/webinar/register/WN_o36Uu7I1T1aT01LZEkcM7A

After registering, you will receive a confirmation email containing information about joining the webinar. The webinar will be recorded and made available on the Investor section of the HeraMED website.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: David@hera-med.com

Company Secretary

Jonathan Hart

T: +61 2 7251 1888

E: Jonathan@hera-med.com

Investor Relations

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

About HeraCARE:

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.